We are analyzing https://link.springer.com/article/10.1007/s00262-009-0699-2.

Title:
An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles | Cancer Immunology, Immunotherapy
Description:
We previously reported peptide vaccine candidates for HLA-A3 supertype (-A3, -A11, -A31, -A33)-positive cancer patients. In the present study, we examined whether those peptides can also induce cytotoxic T lymphocyte (CTL) activity restricted to HLA-A2, HLA-A24, and HLA-A26 alleles. Fourteen peptides were screened for their binding activity to HLA-A*0201, -A*0206, -A*0207, -A*2402, and -A*2601 molecules and then tested for their ability to induce CTL activity in peripheral blood mononuclear cells (PBMCs) from prostate cancer patients. Among these peptides, one from the prostate acid phosphatase protein exhibited binding activity to HLA-A*0201, -A*0206, and -A*2402 molecules. In addition, PBMCs stimulated with this peptide showed that HLA-A2 or HLA-A24 restricted CTL activity. Their cytotoxicity toward cancer cells was ascribed to peptide-specific and CD8+ T cells. These results suggest that this peptide could be widely applicable as a peptide vaccine for HLA-A3 supertype-, HLA-A2-, and -A24-positive cancer patients.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,625,932 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

article, google, scholar, cas, cancer, pubmed, hlaa, peptide, prostate, itoh, patients, immunotherapy, acid, alleles, noguchi, vaccine, immunol, phosphatase, cytotoxic, harada, shichijo, supertype, peptides, ctl, human, hla, class, clin, induce, cells, hlaarestricted, identification, privacy, cookies, content, terasaki, activity, binding, epitope, oncol, res, yamada, takedatsu, prostatic, pathol, publish, research, search, restricted, niu,

Topics {✒️}

epstein-barr virus-induced cytotoxic peptide-based anti-cancer vaccine month download article/chapter hormone-refractory prostate cancer prostate-specific acid phosphatase small-cell lung cancer personalized peptide vaccines human mhc class detect peptide-specific cytotoxic hla-a24-restricted cytotoxic ctl-based tumor therapy prostatic acid phosphatase low-dose estramustine phosphate a24-positive cancer patients antigen-loaded dendritic cells induce cytotoxic t-lymphocytes hla class i-a11 hla-a3 supertype alleles lck-derived peptides applicable induce cancer-reactive cytotoxic mhc class hla-a26 alleles 0201-restricted ctl epitope 01-restricted ctl epitope peptide vaccine candidates phase ii trial prostate-specific antigen multiple hla alleles major hla class article cancer immunology full article pdf anti-cancer vaccine innovative center therapy positive cancer patients hla-a3 supertype hla-a3 supertype cell-based immunotherapy privacy choices/manage cookies induce ctls restricted humoral immune responses personalized peptide vaccination multipeptide vaccines conserved ctl epitopes prostate cancer patients induce ctl activity sart3-derived peptides peptide binding human prostate cancer peptide antigen egfrviii-targeted vaccine

Schema {🗺️}

WebPage:
      mainEntity:
         headline:An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles
         description:We previously reported peptide vaccine candidates for HLA-A3 supertype (-A3, -A11, -A31, -A33)-positive cancer patients. In the present study, we examined whether those peptides can also induce cytotoxic T lymphocyte (CTL) activity restricted to HLA-A2, HLA-A24, and HLA-A26 alleles. Fourteen peptides were screened for their binding activity to HLA-A*0201, -A*0206, -A*0207, -A*2402, and -A*2601 molecules and then tested for their ability to induce CTL activity in peripheral blood mononuclear cells (PBMCs) from prostate cancer patients. Among these peptides, one from the prostate acid phosphatase protein exhibited binding activity to HLA-A*0201, -A*0206, and -A*2402 molecules. In addition, PBMCs stimulated with this peptide showed that HLA-A2 or HLA-A24 restricted CTL activity. Their cytotoxicity toward cancer cells was ascribed to peptide-specific and CD8+ T cells. These results suggest that this peptide could be widely applicable as a peptide vaccine for HLA-A3 supertype-, HLA-A2-, and -A24-positive cancer patients.
         datePublished:2009-03-28T00:00:00Z
         dateModified:2009-03-28T00:00:00Z
         pageStart:1877
         pageEnd:1885
         sameAs:https://doi.org/10.1007/s00262-009-0699-2
         keywords:
            HLA
            Peptide vaccine
            Immunotherapy
            Prostate acid phosphatase
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-009-0699-2/MediaObjects/262_2009_699_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-009-0699-2/MediaObjects/262_2009_699_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-009-0699-2/MediaObjects/262_2009_699_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-009-0699-2/MediaObjects/262_2009_699_Fig4_HTML.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:58
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Yasunobu Terasaki
               affiliation:
                     name:Kurume University School of Medicine
                     address:
                        name:Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
                        type:PostalAddress
                     type:Organization
                     name:Hokkaido University School of Medicine
                     address:
                        name:Department of Surgery, Hokkaido University School of Medicine, Sapporo, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Shigeki Shichijo
               affiliation:
                     name:Kurume University School of Medicine
                     address:
                        name:Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Yamei Niu
               affiliation:
                     name:Kurume University School of Medicine
                     address:
                        name:Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Nobukazu Komatsu
               affiliation:
                     name:Kurume University School of Medicine
                     address:
                        name:Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Masanori Noguchi
               affiliation:
                     name:Kurume University School of Medicine
                     address:
                        name:Department of Urology, Kurume University School of Medicine, Kurume, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Satoru Todo
               affiliation:
                     name:Hokkaido University School of Medicine
                     address:
                        name:Department of Surgery, Hokkaido University School of Medicine, Sapporo, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kyogo Itoh
               affiliation:
                     name:Kurume University School of Medicine
                     address:
                        name:Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles
      description:We previously reported peptide vaccine candidates for HLA-A3 supertype (-A3, -A11, -A31, -A33)-positive cancer patients. In the present study, we examined whether those peptides can also induce cytotoxic T lymphocyte (CTL) activity restricted to HLA-A2, HLA-A24, and HLA-A26 alleles. Fourteen peptides were screened for their binding activity to HLA-A*0201, -A*0206, -A*0207, -A*2402, and -A*2601 molecules and then tested for their ability to induce CTL activity in peripheral blood mononuclear cells (PBMCs) from prostate cancer patients. Among these peptides, one from the prostate acid phosphatase protein exhibited binding activity to HLA-A*0201, -A*0206, and -A*2402 molecules. In addition, PBMCs stimulated with this peptide showed that HLA-A2 or HLA-A24 restricted CTL activity. Their cytotoxicity toward cancer cells was ascribed to peptide-specific and CD8+ T cells. These results suggest that this peptide could be widely applicable as a peptide vaccine for HLA-A3 supertype-, HLA-A2-, and -A24-positive cancer patients.
      datePublished:2009-03-28T00:00:00Z
      dateModified:2009-03-28T00:00:00Z
      pageStart:1877
      pageEnd:1885
      sameAs:https://doi.org/10.1007/s00262-009-0699-2
      keywords:
         HLA
         Peptide vaccine
         Immunotherapy
         Prostate acid phosphatase
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-009-0699-2/MediaObjects/262_2009_699_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-009-0699-2/MediaObjects/262_2009_699_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-009-0699-2/MediaObjects/262_2009_699_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-009-0699-2/MediaObjects/262_2009_699_Fig4_HTML.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:58
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Yasunobu Terasaki
            affiliation:
                  name:Kurume University School of Medicine
                  address:
                     name:Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
                     type:PostalAddress
                  type:Organization
                  name:Hokkaido University School of Medicine
                  address:
                     name:Department of Surgery, Hokkaido University School of Medicine, Sapporo, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Shigeki Shichijo
            affiliation:
                  name:Kurume University School of Medicine
                  address:
                     name:Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Yamei Niu
            affiliation:
                  name:Kurume University School of Medicine
                  address:
                     name:Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Nobukazu Komatsu
            affiliation:
                  name:Kurume University School of Medicine
                  address:
                     name:Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Masanori Noguchi
            affiliation:
                  name:Kurume University School of Medicine
                  address:
                     name:Department of Urology, Kurume University School of Medicine, Kurume, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Satoru Todo
            affiliation:
                  name:Hokkaido University School of Medicine
                  address:
                     name:Department of Surgery, Hokkaido University School of Medicine, Sapporo, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kyogo Itoh
            affiliation:
                  name:Kurume University School of Medicine
                  address:
                     name:Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:58
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Kurume University School of Medicine
      address:
         name:Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
         type:PostalAddress
      name:Hokkaido University School of Medicine
      address:
         name:Department of Surgery, Hokkaido University School of Medicine, Sapporo, Japan
         type:PostalAddress
      name:Kurume University School of Medicine
      address:
         name:Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
         type:PostalAddress
      name:Kurume University School of Medicine
      address:
         name:Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
         type:PostalAddress
      name:Kurume University School of Medicine
      address:
         name:Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
         type:PostalAddress
      name:Kurume University School of Medicine
      address:
         name:Department of Urology, Kurume University School of Medicine, Kurume, Japan
         type:PostalAddress
      name:Hokkaido University School of Medicine
      address:
         name:Department of Surgery, Hokkaido University School of Medicine, Sapporo, Japan
         type:PostalAddress
      name:Kurume University School of Medicine
      address:
         name:Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Yasunobu Terasaki
      affiliation:
            name:Kurume University School of Medicine
            address:
               name:Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
               type:PostalAddress
            type:Organization
            name:Hokkaido University School of Medicine
            address:
               name:Department of Surgery, Hokkaido University School of Medicine, Sapporo, Japan
               type:PostalAddress
            type:Organization
      name:Shigeki Shichijo
      affiliation:
            name:Kurume University School of Medicine
            address:
               name:Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Yamei Niu
      affiliation:
            name:Kurume University School of Medicine
            address:
               name:Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
               type:PostalAddress
            type:Organization
      name:Nobukazu Komatsu
      affiliation:
            name:Kurume University School of Medicine
            address:
               name:Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
               type:PostalAddress
            type:Organization
      name:Masanori Noguchi
      affiliation:
            name:Kurume University School of Medicine
            address:
               name:Department of Urology, Kurume University School of Medicine, Kurume, Japan
               type:PostalAddress
            type:Organization
      name:Satoru Todo
      affiliation:
            name:Hokkaido University School of Medicine
            address:
               name:Department of Surgery, Hokkaido University School of Medicine, Sapporo, Japan
               type:PostalAddress
            type:Organization
      name:Kyogo Itoh
      affiliation:
            name:Kurume University School of Medicine
            address:
               name:Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
      name:Department of Surgery, Hokkaido University School of Medicine, Sapporo, Japan
      name:Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
      name:Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
      name:Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
      name:Department of Urology, Kurume University School of Medicine, Kurume, Japan
      name:Department of Surgery, Hokkaido University School of Medicine, Sapporo, Japan
      name:Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(127)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.39s.

LINK . SPRINGER . COM {}